Patient Care Continuum
In the e-Fusion™ procedure, the leads go in during the fusion, under Direct Visual Placement™. Done the usual way, stimulation comes years later. Most patients with failed back surgery syndrome do not have the opportunity to be indicated for a stimulator to address their chronic pain on average 5.45 years after their first fusion. By then scar tissue can prevent the same placement. Patients in the feasibility study had lived with chronic low back pain for 7.3 years on average.
“a novel technique of integrating DRG stimulation using Direct Visual Placement”
e-Fusion™
Fusion and Ultra Low Energy™ (ULE™) Technology in one procedure, at the first surgery.
Standard of Care
Five or more years of additional fusion surgeries and opioids before a stimulator is even considered.
5+
years on average before neuromodulation is presented as an option to failed back surgery patients
7+
years of chronic pain on average, before feasibility study patients received the e-Fusion™ procedure
Decompression
The surgeon performs an open lumbar decompression at the symptomatic level to address mechanical pain.
Instrumented fusion
The surgeon implants fusion rods and screws to stabilize the spine at the decompressed level.
Direct Visual Placement™
Leads are implanted during the fusion under Direct Visual Placement™ — a technique integrating dorsal root ganglion (DRG) stimulation at the time of surgery.
Single incision
The procedure is designed to be completed through a single incision. This is a design goal. In the published study, the stimulator’s battery was placed through a separate incision.
Performed in the published feasibility studyDesign goal
Source: Park MC, Lall RR, Reddy D, Sembrano JN, Falowski SM, Haider NR. Integrating dorsal root ganglion stimulation with transforaminal lumbar interbody fusion: proof of concept study. (opens in a new tab) North American Spine Society Journal (opens in a new tab), 2026 (15-patient early feasibility study). Results are from early feasibility data and may not be indicative of future outcomes.
See how it works
NeuroFuse® System features
The NeuroFuse® System enables Ultra Low Energy™ (ULE™) Technology at the point of fusion. It is built around what spine surgeons and patients need post surgery.
- Closed loop technology enables sensing at the nerve.
- Being developed with AI-assisted therapy adjustment in mind. These features are not available today.
- Designed to be placed once during the fusion and to provide ongoing Ultra Low Energy™ (ULE™) Technology afterwards, without a separate trial period or a second implant.
NeuroFuse®ULE™ Technology
- Patients adjust their own stimulation via Bluetooth, and surgeons can monitor and treat remotely.
- Implanted during the fusion, so there is no separate procedure to schedule or recover from.
- Stimulation is designed to be adjusted as pain changes, with clinicians reviewing and adjusting remotely.
It is hardware-agnostic: ULE™ Technology is designed to deliver at low energy levels combined with any fusion hardware, making it a highly adaptable procedure. The surgeon keeps whichever interbody cage and pedicle-screw system they already use.
Led by spine surgeons
Patient-focused and integrated
With the patented SynerFuse® e-Fusion™ procedure, Ultra Low Energy™ (ULE™) Technology is added when the surgeon performs the fusion. It is designed to treat neuropathic and mechanical pain.
Surgeon-led
ULE™ Technology was designed by spine surgeons for spine surgeons to improve upon the fusion procedure, developing the e-Fusion™ procedure.
ULE™ technology
ULE™ Technology is designed to deliver at low energy levels combined with any fusion hardware, making it a highly adaptable procedure.
Patent protection
Supported by QuantumStim, SynerFuse Medical holds 13 issued patents protecting its technology across the United States, Canada, Australia, Europe and Asia. The portfolio protects the core concept behind the company’s integrated approach to chronic back pain.
Issued patents
Showing every region where SynerFuse holds issued patents.
Development and manufacturing
Development and manufacturing partner
Med-Ally Medical™
SynerFuse®’s sister company and a division of QuantumStim. Med-Ally Medical™ is an advanced engineering and manufacturing company for Class 2 and Class 3 devices. From concept to commercialization, it is a fully integrated company to design, build and manufacture the NeuroFuse® System, building upon its Patent to Patient™ (P2P) approach.
Plain definitions
- e-Fusion™ (e-TLIF™)
- The SynerFuse® procedure: nerve stimulation placed during a spinal fusion, at the same level, in one operation.
- TLIF
- Transforaminal lumbar interbody fusion, a standard spinal fusion approached through the side of the spinal canal.
- DRG (dorsal root ganglion)
- The cluster of nerve cell bodies that carries pain signals from a specific area of the body.
- Ultra Low Energy™ (ULE™)
- SynerFuse®’s stimulation approach, delivered in the published study at under 1 mA.
- Radiculopathy
- Pain, numbness or weakness travelling along a nerve from a compressed or irritated nerve root.
- Neuromodulation
- Stimulation utilized to treat neuropathic pain.